<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiol Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Radiol Case Rep</journal-id><journal-title-group><journal-title>Radiology Case Reports</journal-title></journal-title-group><issn pub-type="epub">1930-0433</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12097964</article-id><article-id pub-id-type="pii">S1930-0433(25)00337-1</article-id><article-id pub-id-type="doi">10.1016/j.radcr.2025.04.034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Diffuse glioma with <italic>FGFR3</italic>::<italic>TACC3</italic> gene fusion and prominent calcification: A case report</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Kusunoki</surname><given-names>Masaoki</given-names></name><email>kusunoki.masaoki.655@m.kyushu-u.ac.jp</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Togao</surname><given-names>Osamu</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Yamashita</surname><given-names>Koji</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Kikuchi</surname><given-names>Kazufumi</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Kuga</surname><given-names>Daisuke</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0006"><name><surname>Fujioka</surname><given-names>Yutaka</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0007"><name><surname>Akamine</surname><given-names>Shun</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0008"><name><surname>Ishigami</surname><given-names>Kousei</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><aff id="aff0001"><label>a</label>Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</aff><aff id="aff0002"><label>b</label>Department of Molecular Imaging and Diagnosis, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</aff><aff id="aff0003"><label>c</label>Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</aff><aff id="aff0004"><label>d</label>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author. <email>kusunoki.masaoki.655@m.kyushu-u.ac.jp</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>03</day><month>5</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>5</month><year>2025</year></pub-date><volume>20</volume><issue>7</issue><fpage>3540</fpage><lpage>3546</lpage><history><date date-type="received"><day>18</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by Elsevier Inc. on behalf of University of Washington.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0001"><p>Diffuse gliomas with fibroblast growth factor receptor 3 (<italic>FGFR3</italic>) and transforming acidic coiled-coil containing protein 3 (<italic>TACC3</italic>) gene fusion represent a distinct molecular subtype of isocitrate dehydrogenase (IDH)-wildtype gliomas characterized by unique histopathological features. Although microcalcifications have frequently been reported in histopathological studies, their prevalence and diagnostic significance on radiological imaging remain unclear. We report a case of a 67-year-old woman who presented with a 1-year history of weakness in the left lower limb. Head CT revealed coarse and irregular calcifications in the deep white matter of the right frontal and parietal lobes. At the same time, MRI demonstrated a diffuse gliomatosis cerebri-like growth pattern with infiltration across the corpus callosum and contrast enhancement in distant areas. Histopathological examination confirmed glioblastoma, IDH-wildtype, and subsequent genetic testing revealed <italic>FGFR3</italic>::<italic>TACC3</italic> fusion and amplification of <italic>FGFR3</italic> gene. This case highlights the potential radiological characteristics of diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion, particularly the presence of coarse calcifications, that may serve as notable imaging features of this tumor. Further research is required to determine whether calcification is a characteristic of this glioma subtype.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Brain tumor</kwd><kwd>Diffuse glioma</kwd><kwd>Glioblastoma</kwd><kwd>FGFR3</kwd><kwd>TACC3</kwd><kwd>Calcification</kwd></kwd-group></article-meta></front><body><sec id="sec0001"><title>Introduction</title><p id="para0002">In the 2021 World Health Organization (WHO) classification of central nervous system tumors, adult-type diffuse gliomas are broadly categorized into astrocytomas, Isocitrate Dehydrogenase (IDH)-mutant, oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, and glioblastomas, IDH-wildtype [<xref rid="bib0001" ref-type="bibr">1</xref>]. Within the IDH-wildtype subset, diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> gene fusion represent a distinct molecular subtype first identified by Singh et al. in 2012 [<xref rid="bib0002" ref-type="bibr">2</xref>]. This fusion involves fibroblast growth factor receptor 3 (FGFR3) and transforming acidic coiled-coil containing protein 3 (TACC3), leading to the constitutive activation of oncogenic signaling pathways that promote tumor growth and progression [<xref rid="bib0003" ref-type="bibr">3</xref>,<xref rid="bib0004" ref-type="bibr">4</xref>]. <italic>FGFR3</italic>::<italic>TACC3</italic> fusion has been identified in approximately 4% of diffuse gliomas, IDH-wildtype, highlighting the distinct molecular and pathological characteristics that distinguish it from other glioma subtypes [<xref rid="bib0002" ref-type="bibr">2</xref>,<xref rid="bib0005" ref-type="bibr">[5]</xref>, <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>, <xref rid="bib0010" ref-type="bibr">[10]</xref>]. Patients with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive glioblastomas were reported to be similar in age or slightly older at diagnosis compared to those with fusion-negative glioblastomas, with variable reports regarding sex predominance [<xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>].</p><p id="para0003"><italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive gliomas demonstrate a relatively favorable prognosis, with better outcomes than <italic>FGFR3</italic>::<italic>TACC3</italic>-negative glioblastomas, although still poorer than those of IDH-mutant gliomas [<xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>]. The presence of this fusion introduces potential therapeutic options, including FGFR-targeted therapies, highlighting the importance of accurate molecular characterization in guiding treatment decisions [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0011" ref-type="bibr">11</xref>,<xref rid="bib0012" ref-type="bibr">12</xref>]. Notably, the <italic>FGFR3</italic>::<italic>TACC3</italic> fusion plays a role in tumorigenesis in various cancers, including bladder [<xref rid="bib0013" ref-type="bibr">13</xref>], lung [<xref rid="bib0014" ref-type="bibr">14</xref>], and uterine cervical malignancies [<xref rid="bib0015" ref-type="bibr">15</xref>], underscoring its broader oncogenic significance.</p><p id="para0004">These tumors may present with distinctive imaging features, such as prominent calcifications, that can aid in the differential diagnosis. However, the radiological imaging characteristics of <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive gliomas have not yet been fully elucidated, posing challenges in distinguishing them from other diffuse gliomas.</p><p id="para0005">Here, we report a case of diffuse glioma with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion, characterized by striking calcifications and a diffuse infiltrative growth pattern consistent with glioblastoma, IDH-wildtype. This case highlights the importance of integrating radiological, pathological, and molecular findings to improve diagnostic accuracy and inform clinical management.</p></sec><sec id="sec0002"><title>Case presentation</title><p id="para0006">A 67-year-old woman presented to a local hospital with a 1-year history of weakness in the left lower limb. Imaging examinations performed at the hospital suggested the presence of a brain tumor, prompting a referral to the neurosurgery outpatient department. The patient had no notable medical or family history, and laboratory tests revealed no significant abnormalities. At the initial visit to our hospital, she reported subjective weakness in the left lower limb; however, neurological examination did not reveal any apparent motor deficits or other neurological abnormalities. Manual muscle testing (MMT) showed full strength (5/5) in both lower limbs, and deep tendon reflexes and muscle tone were normal. Further imaging studies, including computed tomography (CT) and magnetic resonance imaging (MRI), were performed at our radiology department.</p><p id="para0007">Noncontrast head CT (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>A&#x02013;<xref rid="fig0001" ref-type="fig">C</xref>) revealed multiple irregular and heterogeneous calcifications in the deep white matter from the right frontal to the parietal lobes, predominantly involving the white matter of the medial precentral and postcentral gyri.<fig id="fig0001"><label>Fig. 1</label><caption><p>Head CT findings. Noncontrast CT images of the head in the axial (A), coronal (B), and sagittal (C) views show irregular and heterogeneous coarse calcifications (arrows) in the deep white matter of the right frontal and parietal lobes.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xlink:href="gr1" id="celink0001"/></fig></p><p id="para0008">Brain MRI revealed an ill-defined hyperintense area on T2-weighted images (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>A) and T2-fluid attenuated inversion recovery (FLAIR) imaging (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>B) extending from the deep white matter of the right frontal lobe to the parietal lobes, crossing the corpus callosum to the contralateral white matter (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>A). Correspondingly, high signal intensity on T1-weighted imaging (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>C) and low signal intensity on T2*-weighted imaging (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>D) were observed, indicating calcification in the deep white matter of the right frontal and parietal regions. On diffusion-weighted imaging (DWI; b = 1000 s/mm<sup>2</sup> in 3 orthogonal directions with a slice thickness of 5 mm and an interslice gap of 1 mm), hyperintensities were identified in the lesions within the right frontal to parietal lobes and corpus callosum (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>E). The apparent diffusion coefficient (ADC) value of 0.83 &#x000d7; 10&#x0207b;&#x000b3; mm&#x000b2;/s was comparable to or slightly higher than that of normal white matter (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>E). Contrast-enhanced T1-weighted imaging revealed punctate enhancement in the white matter of the medial aspects of the right precentral and postcentral gyri, as well as the left side of the corpus callosum (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>B).<fig id="fig0002"><label>Fig. 2</label><caption><p>Brain MRI findings. Brain MRI with T2-weighted (A) and FLAIR (B) imaging shows an ill-defined area of high signal intensity extending across the right frontal and parietal lobes. In addition, faint hyperintensity on T1-weighted imaging (C, arrow) and hypointensity on T2*-weighted imaging (D, arrow) in the deep white matter of the right frontal and parietal lobes suggest the presence of calcifications. Diffusion-weighted imaging (E) shows hyperintensity in the deep white matter of the right frontal and parietal lobes, while the apparent diffusion coefficient (ADC) values are comparable to those of the contralateral normal white matter (F, a mean ADC value of 0.83 &#x000d7; 10&#x0207b;&#x000b3; mm&#x000b2;/s in the area indicated by the arrow).</p></caption><alt-text id="alt0002">Fig 2</alt-text><graphic xlink:href="gr2" id="celink0002"/></fig><fig id="fig0003"><label>Fig. 3</label><caption><p>Brain MRI findings. Brain MRI in coronal view at initial evaluation at our hospital shows that the ill-defined high signal intensity area on FLAIR imaging (A) extends to the left side of the corpus callosum, with enhancement observed in the medial right precentral and postcentral gyri as well as the left corpus callosum on contrast-enhanced T1-weighted imaging (B, arrows). Follow-up MRI 2 months later shows no change in the ill-defined high signal intensity area on FLAIR imaging (C); however, enlargement of the enhancing lesions and ring-like enhancement are noted on contrast-enhanced T1-weighted imaging (D, arrows).</p></caption><alt-text id="alt0003">Fig 3</alt-text><graphic xlink:href="gr3" id="celink0003"/></fig></p><p id="para0009">Two months later, follow-up MRI revealed no significant changes in the ill-defined T2 prolongation (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>C), but enlargement of the enhancing lesions in the white matter of the medial right precentral and postcentral gyri and the left side of the corpus callosum formed a ring-like shape (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>D). Glioblastoma, IDH wildtype, was strongly suspected, and a stereotactic brain tumor biopsy was performed targeting the lesion on the left side of the corpus callosum for diagnostic confirmation.</p><p id="para0010">Histopathological and molecular analyses of the biopsied lesion confirmed the diagnosis of glioblastoma, IDH-wildtype. Histopathological examination revealed diffuse proliferation of anaplastic glioma cells with enlarged, pleomorphic nuclei (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>A). Focal mitotic figures were observed (5/10 high-power fields), and microvascular proliferation was suspected (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>B); however, palisading necrosis was not evident. Additionally, no microcalcifications were observed in the biopsy specimens, possibly due to the location of the sampling site.<fig id="fig0004"><label>Fig. 4</label><caption><p>Histopathological findings. Biopsy specimen obtained from the left side of the corpus callosum (hematoxylin and eosin staining) shows diffuse proliferation of glioma cells at low magnification (A) and microvascular proliferation at high magnification (B, arrows).</p></caption><alt-text id="alt0004">Fig 4</alt-text><graphic xlink:href="gr4" id="celink0004"/></fig></p><p id="para0011">Immunohistochemical staining revealed that the glioma cells were focally positive for p16 and p53, negative for IDH1 R132H, and retained ATRX and MTAP. The MIB-1 labeling index was 10%. Molecular analysis revealed IDH1/2-wildtype, 1p/19q noncodeletion, <italic>BRAF</italic> wildtype, <italic>TERT</italic> promoter mutation, <italic>EGFR</italic> gene copy number gain, and <italic>MGMT</italic> promoter methylation. Based on these findings, a diagnosis of glioblastoma, IDH-wildtype was made according to the 2021 updated 5th WHO Classification of Tumors of the Central Nervous System (WHO CNS5) criteria.</p><p id="para0012">Subsequently, the patient underwent chemoradiotherapy with temozolomide and maintenance chemotherapy with bevacizumab and/or temozolomide. With the patient&#x02019;s consent, a cancer gene panel test was performed, which identified <italic>FGFR3</italic>::<italic>TACC3</italic> fusion (F17*; T4) and <italic>FGFR3</italic> amplification (copy number = 10). Follow-up MRI examinations performed over &#x0003e; 18 months showed no worsening of symptoms or lesion progression.</p></sec><sec id="sec0003"><title>Discussion</title><p id="para0013">Diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> gene fusion were first identified as distinct disease entities by Singh et al. in 2012 [<xref rid="bib0002" ref-type="bibr">2</xref>]. This fusion-type glioma is recognized for its unique molecular and pathological characteristics that differentiate it from other gliomas [<xref rid="bib0009" ref-type="bibr">9</xref>]. <italic>FGFR3</italic>::<italic>TACC3</italic> fusion occurs in approximately 4% of glioblastomas, IDH-wildtype and a similar proportion of diffuse gliomas, IDH-wildtype with lower-grade histology [<xref rid="bib0002" ref-type="bibr">2</xref>,<xref rid="bib0005" ref-type="bibr">[5]</xref>, <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>,<xref rid="bib0010" ref-type="bibr">10</xref>]. Patients with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive glioblastomas were reported to be similar in age or slightly older at diagnosis, with no significant differences in laterality or anatomical localization compared to those with fusion-negative glioblastomas [<xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>]. The <italic>FGFR3</italic>::<italic>TACC3</italic> fusion results from the juxtaposition of <italic>FGFR3</italic>, encoding a receptor tyrosine kinase involved in cell proliferation and growth, and <italic>TACC3</italic>, encoding a microtubule-associated protein implicated in mitotic spindle stabilization [<xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>]. These genes, located 48 kb apart on chromosome 4p16, fuse to drive oncogenesis by activating multiple signaling pathways, including MAPK, PI3K/AKT, and those involved in metabolic reprogramming through mitochondrial biogenesis and oxidative phosphorylation [<xref rid="bib0002" ref-type="bibr">2</xref>,<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0020" ref-type="bibr">20</xref>]. Molecularly, these tumors are negative for IDH1/2 mutations, 1p/19q codeletions, <italic>H3</italic> mutations, and BRAF p.V600E mutations, with rare EGFR amplification (0-5.6%) [<xref rid="bib0005" ref-type="bibr">[5]</xref>, <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>]. Immunohistochemical staining for <italic>FGFR3</italic> demonstrated high sensitivity and specificity for detecting the <italic>FGFR</italic>3::<italic>TACC</italic>3 fusion protein, with reported values of 100% and 92% [<xref rid="bib0021" ref-type="bibr">21</xref>], and 93% and 95% [<xref rid="bib0022" ref-type="bibr">22</xref>], respectively. Given its high diagnostic accuracy, FGFR3 immunostaining may serve as a useful screening tool prior to genetic testing. In addition, recent studies have reported that RT-qPCR screening of formalin-fixed, paraffin-embedded samples achieves high sensitivity (100%) and specificity (83.3%), further supporting its potential for clinical application [<xref rid="bib0023" ref-type="bibr">23</xref>]. Diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion have an intermediate prognosis, with poorer survival outcomes than IDH-mutant gliomas but superior outcomes compared to <italic>FGFR3</italic>::<italic>TACC3</italic>-negative glioblastomas [<xref rid="bib0007" ref-type="bibr">7</xref>]. In a recent study, the median overall survival of <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive glioblastomas was reported to be 31.1 months, significantly longer than that of fusion-negative glioblastomas (19.9 months), with the fusion serving as an independent predictor of better outcome [<xref rid="bib0007" ref-type="bibr">7</xref>]. These tumors may also respond to FGFR inhibitors [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0011" ref-type="bibr">11</xref>,<xref rid="bib0012" ref-type="bibr">12</xref>], emphasizing the critical role of molecular testing in guiding targeted therapies.</p><p id="para0014">Histopathologically, diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion frequently exhibit microcalcifications, nuclear palisading, and curvilinear capillary proliferation, which have been reported to be significantly more prominent than those in <italic>FGFR3</italic>::<italic>TACC3</italic>-negative glioblastomas [<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0024" ref-type="bibr">24</xref>]. Additionally, perivascular pseudorosette formation and oligodendroglial-like cells have been observed, although their diagnostic relevance remains unclear [<xref rid="bib0009" ref-type="bibr">9</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>]. In the present case, the biopsy specimen obtained from the left side of the corpus callosum did not exhibit these characteristic features. Biopsies of the right frontal and parietal white matter, where calcifications were more prominent, were avoided because of the risk of motor neuron injury. It is plausible that specimens from this region exhibit more typical histological features. This suggests that histopathological differences may exist between rapidly growing, contrast-enhancing lesions and areas with prominent calcification. Molecular analysis confirmed IDH1/2-wildtype status, absence of 1p/19q codeletion, and presence of a <italic>TERT</italic> promoter mutation, consistent with glioblastoma IDH-wildtype per the WHO CNS5 criteria [<xref rid="bib0001" ref-type="bibr">1</xref>]. These molecular features are consistent with those reported previously, and no unique findings were observed in our case.</p><p id="para0015">MRI depicts the histopathological features of glioblastoma, including tumor infiltration, angiogenesis, and necrosis, which are characterized by ill-defined, diffusely infiltrative mass lesions with heterogeneous high signal intensity on T2-weighted and FLAIR imaging. Contrast enhancement varies and may present as a solid, ring-like, nodular, or patchy pattern, possibly in multiple locations. Gliomatosis cerebri-like growth patterns are frequently observed in glioblastomas, particularly in IDH-wildtype cases, reflecting their highly infiltrative nature [<xref rid="bib0025" ref-type="bibr">25</xref>]. Previous radiological imaging studies of <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive gliomas have reported a tendency for these tumors to localize to the cortex or subcortical white matter, particularly in the frontal or temporal lobes, with relatively well-circumscribed margins in a subset of cases based on MRI [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0008" ref-type="bibr">8</xref>]. Contrast enhancement patterns are variable, ranging from minimal to ring-like enhancement, and tumor borders may appear either well-circumscribed or poorly defined [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0026" ref-type="bibr">26</xref>,<xref rid="bib0027" ref-type="bibr">27</xref>]. Taken together, these findings suggest a wide spectrum of radiological appearances in <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive gliomas. Given that glioblastomas in general exhibit considerable radiological diversity, the imaging features in our case would fall within the range described in previous reports.</p><p id="para0016">However, the prevalence of radiologically detectable calcifications on CT and/or MRI in <italic>FGFR3</italic>::<italic>TACC3-</italic>positive diffuse gliomas remains unclear. On MRI, the calcium-induced T1 shortening, which depends on its concentration within the tissue, can result in hyperintensity on T1-weighted images [<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0029" ref-type="bibr">29</xref>]. These imaging findings may also reflect microcalcifications frequently reported in the histopathology of <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive gliomas [<xref rid="bib0027" ref-type="bibr">27</xref>]. Although this correlates with the frequent microcalcifications observed on histopathological examinations, comprehensive imaging-based analyses remain limited. If calcification is a characteristic feature, radiological imaging can significantly enhance diagnostic accuracy. Further studies are needed to compare the frequency and distribution of calcifications in <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-positive and -negative IDH-wildtype glioblastomas.</p><p id="para0017">Considering the presence of calcifications, differential diagnoses include <italic>FGFR3</italic>::<italic>TACC3</italic> fusion-negative glioblastoma, oligodendroglioma, ependymoma, ganglioglioma, and polymorphous low-grade neuroepithelial tumors of the young (PLNTY). Among these, oligodendrogliomas, IDH-mutant, and 1p/19q-codeleted are typically located in the frontal lobe with cortical-subcortical involvement, commonly occur in younger adults, and may exhibit a cortical high-flow sign on arterial spin labeling (ASL), aiding in their noninvasive differentiation from other diffuse gliomas [<xref rid="bib0030" ref-type="bibr">30</xref>]. Supratentorial ependymomas in adults can mimic diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion when displaying infiltrative growth. In contrast, gangliogliomas and PLNTYs, classified as WHO CNS5 grade 1 tumors, have low malignant potential, lack diffuse infiltration, and primarily affect individuals from childhood to young adulthood.</p><p id="para0018">In the present case, the gliomatosis cerebri-like growth pattern, characterized by diffuse infiltration across the corpus callosum with contrast enhancement in distant areas, was highly suggestive of glioblastoma, IDH-wildtype. Notably, coarse calcifications in the deep white matter have emerged as a distinctive radiological feature that may aid in differentiating diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion from fusion-negative glioblastomas. While previous reports have suggested an association between <italic>FGFR3</italic>::<italic>TACC3</italic> fusion and microcalcifications on histopathological examination, their prominence in radiological imaging underscores the need for further research to clarify their diagnostic and clinical relevance. As molecular characterization increasingly guides therapeutic decision-making, recognizing such radiological features may enhance diagnostic accuracy and support the early identification of patients who could benefit from FGFR-targeted therapies.</p></sec><sec id="sec0004"><title>Conclusion</title><p id="para0019">Diffuse gliomas with <italic>FGFR3</italic>::<italic>TACC3</italic> fusion constitute a distinct molecular subtype with potentially unique radiological features, particularly prominent calcifications with an infiltrative tumor growth pattern suggestive of glioblastoma, IDH-wildtype, which may serve as a useful diagnostic marker. Accurate identification of this entity is essential, given its intermediate prognosis and potential responsiveness to FGFR-targeted therapies. Further studies are warranted to elucidate the clinical significance of calcifications and refine the diagnostic and therapeutic approaches for affected patients.</p></sec><sec id="sec0005"><title>Patient consent</title><p id="para0020">The patient provided written informed consent for the publication of this case study.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>D.N.</given-names></name><name><surname>Perry</surname><given-names>A.</given-names></name><name><surname>Wesseling</surname><given-names>P.</given-names></name><name><surname>Brat</surname><given-names>D.J.</given-names></name><name><surname>Cree</surname><given-names>I.A.</given-names></name><name><surname>Figarella-Branger</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The 2021 WHO classification of tumors of the central nervous system: a summary</article-title><source>Neuro Oncol</source><year>2021</year><pub-id pub-id-type="doi">10.1093/neuonc/noab106</pub-id><comment>23-1231&#x02013;51</comment></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D.</given-names></name><name><surname>Chan</surname><given-names>J.M.</given-names></name><name><surname>Zoppoli</surname><given-names>P.</given-names></name><name><surname>Niola</surname><given-names>F.</given-names></name><name><surname>Sullivan</surname><given-names>R.</given-names></name><name><surname>Castano</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Transforming fusions of FGFR and TACC genes in human glioblastoma</article-title><source>Science</source><volume>337</volume><year>2012</year><fpage>1231</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1126/science.1220834</pub-id><pub-id pub-id-type="pmid">22837387</pub-id>
</element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>B.C.</given-names></name><name><surname>Annala</surname><given-names>M.J.</given-names></name><name><surname>Cogdell</surname><given-names>D.E.</given-names></name><name><surname>Granberg</surname><given-names>K.J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Ji</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma</article-title><source>J Clin Invest</source><year>2013</year><pub-id pub-id-type="doi">10.1172/JCI67144</pub-id><comment>123-855&#x02013;65</comment></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Touat</surname><given-names>M.</given-names></name><name><surname>Ileana</surname><given-names>E.</given-names></name><name><surname>Postel-Vinay</surname><given-names>S.</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F.</given-names></name><name><surname>Soria</surname><given-names>J-C</given-names></name></person-group><article-title>Targeting FGFR signaling in cancer</article-title><source>Clin Cancer Res</source><volume>21</volume><year>2015</year><fpage>2684</fpage><lpage>2694</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2329</pub-id><pub-id pub-id-type="pmid">26078430</pub-id>
</element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Di Stefano</surname><given-names>A.L.</given-names></name><name><surname>Fucci</surname><given-names>A.</given-names></name><name><surname>Frattini</surname><given-names>V.</given-names></name><name><surname>Labussiere</surname><given-names>M.</given-names></name><name><surname>Mokhtari</surname><given-names>K.</given-names></name><name><surname>Zoppoli</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Detection, characterization, and inhibition of FGFR&#x02013;TACC fusions in IDH wild-type glioma</article-title><source>Clin Cancer Res</source><volume>21</volume><year>2015</year><fpage>3307</fpage><lpage>3317</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2199</pub-id><pub-id pub-id-type="pmid">25609060</pub-id>
</element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Mata</surname><given-names>D.A.</given-names></name><name><surname>Benhamida</surname><given-names>J.K.</given-names></name><name><surname>Lin</surname><given-names>A.L.</given-names></name><name><surname>Vanderbilt</surname><given-names>C.M.</given-names></name><name><surname>Yang</surname><given-names>S-R</given-names></name><name><surname>Villafania</surname><given-names>L.B.</given-names></name><etal/></person-group><article-title>Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions</article-title><source>Acta Neuropathol Commun</source><volume>8</volume><year>2020</year><fpage>186</fpage><pub-id pub-id-type="doi">10.1186/s40478-020-01058-6</pub-id><pub-id pub-id-type="pmid">33168106</pub-id>
</element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Di Stefano</surname><given-names>A.L.</given-names></name><name><surname>Picca</surname><given-names>A.</given-names></name><name><surname>Saragoussi</surname><given-names>E.</given-names></name><name><surname>Bielle</surname><given-names>F.</given-names></name><name><surname>Ducray</surname><given-names>F.</given-names></name><name><surname>Villa</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions</article-title><source>Neuro Oncol</source><volume>22</volume><year>2020</year><fpage>1614</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noaa121</pub-id><pub-id pub-id-type="pmid">32413119</pub-id>
</element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Suh</surname><given-names>Y.L.</given-names></name></person-group><article-title>Clinicopathological and molecular characteristics of IDH-wildtype glioblastoma with FGFR3-TACC3 fusion</article-title><source>Biomedicines</source><volume>12</volume><year>2024</year><fpage>150</fpage><pub-id pub-id-type="doi">10.3390/biomedicines12010150</pub-id><pub-id pub-id-type="pmid">38255255</pub-id>
</element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Marastoni</surname><given-names>E.</given-names></name><name><surname>Mulone</surname><given-names>D.</given-names></name><name><surname>Barresi</surname><given-names>V.</given-names></name></person-group><article-title>Diffuse gliomas with FGFR3-TACC3 fusion: morphological and molecular features and classification challenges</article-title><source>Cancers (Basel)</source><volume>16</volume><year>2024</year><fpage>1644</fpage><pub-id pub-id-type="doi">10.3390/cancers16091644</pub-id><pub-id pub-id-type="pmid">38730596</pub-id>
</element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>M&#x000e9;tais</surname><given-names>A.</given-names></name><name><surname>Tauzi&#x000e8;de-Espariat</surname><given-names>A.</given-names></name><name><surname>Garcia</surname><given-names>J.</given-names></name><name><surname>Appay</surname><given-names>R.</given-names></name><name><surname>Uro-Coste</surname><given-names>E.</given-names></name><name><surname>Meyronet</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3-TACC3 fusion</article-title><source>Acta Neuropathol Commun</source><volume>11</volume><year>2023</year><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s40478-023-01506-z</pub-id><pub-id pub-id-type="pmid">36647073</pub-id>
</element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Su</surname><given-names>F.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Khazanov</surname><given-names>N.</given-names></name><name><surname>Ateeq</surname><given-names>B.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Identification of targetable FGFR gene fusions in diverse cancers</article-title><source>Cancer Discov</source><year>2013</year><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0050</pub-id><comment>3-636&#x02013;47</comment></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Picca</surname><given-names>A.</given-names></name><name><surname>Di Stefano</surname><given-names>A.L.</given-names></name><name><surname>Savatovsky</surname><given-names>J.</given-names></name><name><surname>Ducray</surname><given-names>F.</given-names></name><name><surname>Chinot</surname><given-names>O.</given-names></name><name><surname>Moyal</surname><given-names>EC-J</given-names></name><etal/></person-group><article-title>TARGET: a phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma</article-title><source>Neurooncol Adv</source><volume>6</volume><year>2024</year><fpage>vdae068</fpage><pub-id pub-id-type="doi">10.1093/noajnl/vdae068</pub-id><pub-id pub-id-type="pmid">38813112</pub-id>
</element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>S.V.</given-names></name><name><surname>Hurst</surname><given-names>C.D.</given-names></name><name><surname>Knowles</surname><given-names>M.A.</given-names></name></person-group><article-title>Oncogenic FGFR3 gene fusions in bladder cancer</article-title><source>Hum Mol Genet</source><volume>22</volume><year>2013</year><fpage>795</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds486</pub-id><pub-id pub-id-type="pmid">23175443</pub-id>
</element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of nonsmall cell lung cancer</article-title><source>Clin Cancer Res</source><volume>20</volume><year>2014</year><fpage>4107</fpage><lpage>4114</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0284</pub-id><pub-id pub-id-type="pmid">24850843</pub-id>
</element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>B.A.</given-names></name><name><surname>Elvin</surname><given-names>J.A.</given-names></name><name><surname>Kamath</surname><given-names>S.D.</given-names></name><name><surname>Ali</surname><given-names>S.M.</given-names></name><name><surname>Paintal</surname><given-names>A.S.</given-names></name><name><surname>Restrepo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>FGFR3-TACC3&#x02014;a novel gene fusion in cervical cancer</article-title><source>Gynecol Oncol Rep</source><year>2015</year><pub-id pub-id-type="doi">10.1016/j.gore.2015.06.005</pub-id><comment>13-53&#x02013;6</comment></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Bocharov</surname><given-names>E.V.</given-names></name><name><surname>Lesovoy</surname><given-names>D.M.</given-names></name><name><surname>Goncharuk</surname><given-names>S.A.</given-names></name><name><surname>Goncharuk</surname><given-names>M.V.</given-names></name><name><surname>Hristova</surname><given-names>K.</given-names></name><name><surname>Arseniev</surname><given-names>A.S.</given-names></name></person-group><article-title>Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies</article-title><source>Structure</source><volume>21</volume><year>2013</year><fpage>2087</fpage><lpage>2093</lpage><pub-id pub-id-type="doi">10.1016/j.str.2013.08.026</pub-id><pub-id pub-id-type="pmid">24120763</pub-id>
</element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Z-M</given-names></name><name><surname>Huang</surname><given-names>C-J</given-names></name><name><surname>Jiao</surname><given-names>X-F</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Huo</surname><given-names>L-J</given-names></name></person-group><article-title>The role of TACC3 in mitotic spindle organization</article-title><source>Cytoskeleton (Hoboken)</source><volume>74</volume><year>2017</year><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1002/cm.21388</pub-id><pub-id pub-id-type="pmid">28745816</pub-id>
</element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>FGF/FGFR signaling in health and disease</article-title><source>Signal Transduct Target Ther</source><volume>5</volume><year>2020</year><fpage>181</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-00222-7</pub-id><pub-id pub-id-type="pmid">32879300</pub-id>
</element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name><surname>Frattini</surname><given-names>V.</given-names></name><name><surname>Pagnotta</surname><given-names>S.M.</given-names></name><name><surname>Tala</surname><given-names>F.J.J.</given-names></name><name><surname>Fan</surname><given-names>J.J.</given-names></name><name><surname>Russo</surname><given-names>M.V.</given-names></name><name><surname>Lee</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>A metabolic function of FGFR3-TACC3 gene fusions in cancer</article-title><source>Nature</source><year>2018</year><pub-id pub-id-type="doi">10.1038/nature25171</pub-id><comment>553-222&#x02013;7</comment></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>G&#x000f6;tt</surname><given-names>H.</given-names></name><name><surname>Uhl</surname><given-names>E.</given-names></name></person-group><article-title>FGFR3-TACCs3 fusions and their clinical relevance in human glioblastoma</article-title><source>Int J Mol Sci</source><year>2022</year><fpage>23</fpage><lpage>8675</lpage><pub-id pub-id-type="doi">10.3390/ijms23158675</pub-id><pub-id pub-id-type="pmid">36613467</pub-id>
</element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Bielle</surname><given-names>F.</given-names></name><name><surname>Di</surname><given-names>SA-L</given-names></name><name><surname>Meyronet</surname><given-names>D.</given-names></name><name><surname>Picca</surname><given-names>A.</given-names></name><name><surname>Villa</surname><given-names>C.</given-names></name><name><surname>Bernier</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features</article-title><source>Brain Pathol</source><volume>28</volume><year>2018</year><fpage>674</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1111/bpa.12563</pub-id><pub-id pub-id-type="pmid">28976058</pub-id>
</element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name><surname>Schittenhelm</surname><given-names>J.</given-names></name><name><surname>Ziegler</surname><given-names>L.</given-names></name><name><surname>Sperveslage</surname><given-names>J.</given-names></name><name><surname>Mittelbronn</surname><given-names>M.</given-names></name><name><surname>Capper</surname><given-names>D.</given-names></name><name><surname>Burghardt</surname><given-names>I.</given-names></name><etal/></person-group><article-title>FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma</article-title><source>Neurooncol Pract</source><volume>8</volume><year>2021</year><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1093/nop/npaa075</pub-id><pub-id pub-id-type="pmid">33898054</pub-id>
</element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name><surname>Priesterbach-Ackley</surname><given-names>L.P.</given-names></name><name><surname>van Kuik</surname><given-names>J.</given-names></name><name><surname>Tops</surname><given-names>B.B.J.</given-names></name><name><surname>Lasorella</surname><given-names>A.</given-names></name><name><surname>Iavarone</surname><given-names>A.</given-names></name><name><surname>van Hecke</surname><given-names>W.</given-names></name><etal/></person-group><article-title>RT-PCR assay to detect FGFR3-TACC3 fusions in formalin-fixed, paraffin-embedded glioblastoma samples</article-title><source>Neurooncol Pract</source><volume>11</volume><year>2024</year><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1093/nop/npad081</pub-id><pub-id pub-id-type="pmid">38496910</pub-id>
</element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name><surname>Gilani</surname><given-names>A.</given-names></name><name><surname>Davies</surname><given-names>K.D.</given-names></name><name><surname>Kleinschmidt-DeMasters</surname><given-names>B.K.</given-names></name></person-group><article-title>Can adult IDH-wildtype glioblastomas with <italic>FGFR3-TACC3</italic> fusions be reliably predicted by histological features?</article-title><source>Clin Neuropathol</source><volume>40</volume><year>2021</year><fpage>165</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.5414/NP301357</pub-id><pub-id pub-id-type="pmid">33769273</pub-id>
</element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>I.</given-names></name><name><surname>Park</surname><given-names>Y.W.</given-names></name><name><surname>Sim</surname><given-names>Y.</given-names></name><name><surname>Choi</surname><given-names>S.H.</given-names></name><name><surname>Ahn</surname><given-names>S.S.</given-names></name><name><surname>Chang</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Revisiting gliomatosis cerebri in adult-type diffuse gliomas: a comprehensive imaging, genomic and clinical analysis</article-title><source>Acta Neuropathol Commun</source><volume>12</volume><year>2024</year><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s40478-024-01832-w</pub-id><pub-id pub-id-type="pmid">39127694</pub-id>
</element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>M.F.</given-names></name><name><surname>Athukuri</surname><given-names>P.</given-names></name><name><surname>Anand</surname><given-names>A.</given-names></name><name><surname>Gopakumar</surname><given-names>S.</given-names></name><name><surname>Jalali</surname><given-names>A.</given-names></name><name><surname>Patel</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas</article-title><source>Neurosurg Focus</source><volume>53</volume><issue>6</issue><year>2022</year><fpage>E16</fpage><pub-id pub-id-type="doi">10.3171/2022.9.FOCUS22420</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name><surname>Martelli</surname><given-names>F.M.</given-names></name><name><surname>Marastoni</surname><given-names>E.</given-names></name><name><surname>Barresi</surname><given-names>V.</given-names></name></person-group><article-title>A diffuse glioma with oligodendroglial-like cells and extensive calcifications</article-title><source>Brain Pathol</source><volume>34</volume><year>2024</year><object-id pub-id-type="publisher-id">e13187</object-id><pub-id pub-id-type="doi">10.1111/bpa.13187</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name><surname>Avrahami</surname><given-names>E.</given-names></name><name><surname>Cohn</surname><given-names>D.F.</given-names></name><name><surname>Feibel</surname><given-names>M.</given-names></name><name><surname>Tadmor</surname><given-names>R.</given-names></name></person-group><article-title>MRI demonstration and CT correlation of the brain in patients with idiopathic intracerebral calcification</article-title><source>J Neurol</source><volume>241</volume><year>1994</year><fpage>381</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1007/BF02033355</pub-id><pub-id pub-id-type="pmid">7931433</pub-id>
</element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name><surname>Ginat</surname><given-names>D.T.</given-names></name><name><surname>Meyers</surname><given-names>S.P.</given-names></name></person-group><article-title>Intracranial lesions with high signal intensity on T1-weighted MR images: differential diagnosis</article-title><source>RadioGraphics</source><volume>32</volume><year>2012</year><fpage>499</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1148/rg.322105761</pub-id><pub-id pub-id-type="pmid">22411945</pub-id>
</element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>K.</given-names></name><name><surname>Togao</surname><given-names>O.</given-names></name><name><surname>Kikuchi</surname><given-names>K.</given-names></name><name><surname>Kuga</surname><given-names>D.</given-names></name><name><surname>Sangatsuda</surname><given-names>Y.</given-names></name><name><surname>Fujioka</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Cortical high-flow sign on arterial spin labeling: a novel biomarker for IDH-mutation and 1p/19q-codeletion status in diffuse gliomas without intense contrast enhancement</article-title><source>Neuroradiology</source><volume>65</volume><year>2023</year><fpage>1415</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1007/s00234-023-03186-x</pub-id><pub-id pub-id-type="pmid">37367991</pub-id>
</element-citation></ref></ref-list><fn-group><fn id="d36e42"><p id="notep0001">Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></fn></fn-group></back></article>